Expanded Access Protocol for Product which does not conform to the TECELRA (Afamitresgene autoleucel, suspension for intravenous infusion) Commercial Release Specification.

Disease Sites:

Sarcoma

Staging:

N/A

Age Group:

Adults

Therapies:

Chemotherapy - cytotoxic, Mol. targeted/Immunotherapy/Biologics

Drugs:

Cyclophosphamide, Fludarabine

Principal Investigator(s):

Keedy, Vicki

Scope:

National

Participating Institutions:

Vanderbilt University

Open Date:

07-08-2025

Trial Type:

Treatment

Protocol ID:

VICCSAR24510

National Clinical Trial ID:

NCT06617572

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available